Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.

December 7, 2012

Atlanta, Georgia

Continuing Medical Education

Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this live educational activity for a maximum of 3.25 AMA PRA Category 1 CreditTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Who Should Attend

This educational activity is specifically designed for community oncologists, hematologists, and other physicians, clinicians, physicians-in-training, and health-care professionals (oncology nurses, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with myelofibrosis.

Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Summarize current knowledge of the pathobiology of myelofibrosis and the clinical significance of JAK2 V617F and other mutations
  • Stratify patient risk and formulate risk-adapted treatment plans for myelofibrosis
  • Evaluate the potential of JAK inhibitors to manage myelofibrosis and select appropriate JAK inhibitor therapy based on a patient's profile
  • Review ongoing clinical trials of JAK inhibitors and other novel targeted agents for MF

The proposed activity will compare the planned (post-activity) versus current (pre-activity) frequency of use of the following clinical practice strategies:

  • Stratify patient risk and formulate risk-adapted treatment plans for myelofibrosis
  • Identify myelofibrosis patients who may benefit from JAK inhibitors
  • Enroll myelofibrosis patients in clinical trials of novel targeted agents

The following ACGME/ABMS Core Competencies will be addressed in this activity:

  • Medical Knowledge
  • Practice-Based Learning and Improvement